Cargando…

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants. Cyclin Dependent Kinase inhibitors (CDKi) are at the front-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buzzetti, Marta, Morlando, Sonia, Solomos, Dimitrios, Mehmood, Ammara, Cox, Alexander W. I., Chiesa, Mattia, D’Alessandra, Yuri, Garofalo, Michela, Topham, Caroline H., Di Leva, Gianpiero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940474/ https://www.ncbi.nlm.nih.gov/pubmed/33686114 http://dx.doi.org/10.1038/s41598-021-84082-3

Ejemplares similares

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
por: Taylor, Louisa, et al.
Publicado: (2023)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
por: Ke, Changhong, et al.
Publicado: (2020)

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
por: Shen, Xiao, et al.
Publicado: (2023)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity In Vivo
por: Ruggeri, Clarissa, et al.
Publicado: (2018)

Differential Role of Circulating microRNAs to Track Progression and Pre-Symptomatic Stage of Chronic Heart Failure: A Pilot Study
por: D’Alessandra, Yuri, et al.
Publicado: (2020)

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
por: Pitolli, Consuelo, et al.
Publicado: (2023)

Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1‐involved pathway
por: Zhao, Huayan, et al.
Publicado: (2019)

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
por: Howard, David, et al.
Publicado: (2021)

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
por: Gregory, G P, et al.
Publicado: (2015)

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy
por: Yuan, Qian, et al.
Publicado: (2022)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Diabetes Induces a Transcriptional Signature in Bone Marrow–Derived CD34(+) Hematopoietic Stem Cells Predictive of Their Progeny Dysfunction
por: D’Alessandra, Yuri, et al.
Publicado: (2021)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
por: Paliouras, Athanasios R, et al.
Publicado: (2020)

Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients
por: Ruggeri, Clarissa, et al.
Publicado: (2017)

Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
por: Gioffré, Sonia, et al.
Publicado: (2020)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

Evaluation of Oxford Nanopore MinION RNA-Seq Performance for Human Primary Cells
por: Massaiu, Ilaria, et al.
Publicado: (2021)

DDRE-02. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

EMBR-16. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
por: Tang, Hailong, et al.
Publicado: (2018)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
por: Nelson, Luke J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bh500usuuresqkhktcjdqgh1eq